trial · primary record
Remigromig
Neovascular Age-related Macular Degeneration (NVAMD)
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 33 |
| Primary completion | 2024-08-26 |
| Primary endpoint | Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) |
| Registry ID | NCT05919693 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:33.805Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05919693
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.